Response rates decrease with each subsequent line of therapy2

Response rates by line of therapy2*

Response rate chart Response rate chart

Pinch to zoom

*Data from a retrospective analysis of 404 patients with MCL treated at Memorial Sloan Kettering from 2000 to 2014.1

Due to rounding, the percentages of complete response and partial response may differ from the objective response rate percentage.


While outcomes have improved with the recent emergence of treatment options for relapsed/refractory disease, long-term outcomes remain poor3

Progression-free survival decreases by each subsequent line of therapy (P<0.01)1*

Progression-free survival graph Progression-free survival graph

Pinch to zoom

*Data from a retrospective analysis of 404 patients with MCL treated at Memorial Sloan Kettering from 2000 to 2014.1

MCL=mantle cell lymphoma; mPFS=median progression-free survival; ORR=objective response rate; R/R=relapsed or refractory.

References: 1. Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9(50):1-10. 2. Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse - supplemental data. Blood Cancer J. 2019;9(suppl):1-7. 3. Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430-438.